Cancer Therapy

Tubercin being tested on mice with cancer

Published in Immunotherapy Weekly, October 8th, 2003

Hard to Treat Diseases, Inc., (HTDS) announced that it has commenced talks with a medical group in a concerted effort regarding the testing of Tubercin in experiments with mice infected with cancer.

The rationale is that these preliminary tests would be helpful for further U.S. Food and Drug Administration considerations as well as reinforcement of results that the inventor of Tubercin has established in the past in Korea and elsewhere.

The expectation of HTTD is that scientific results recorded by a third party other than those associated with HTTD will further the company's communication efforts in establishing Tubercin as an immunostimulant for...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Immunotherapy Weekly

Source: Immunotherapy Weekly (2003-10-08)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry